Brain Tumor Drugs Market to Exhibit 10.4% CAGR till 2028; Collaborations to Develop New Drugs for Patients will Augment Growth, says Fortune Business Insights™

The global brain tumor drugs market size is projected to reach USD 5.64 billion in 2028. Governments of various countries are constantly trying to improve the healthcare infrastructure. Besides, multiple pharmaceutical companies are engaging in partnerships and collaborations to develop new brain tumor drugs. In May 2020, for instance, Perelman School of Medicine joined hands with Intel to accelerate a unique distributed machine learning technique. It would enable researchers worldwide to work together for developing novel deep learning initiatives without sharing data. Fortune Business Insights™ published this information in a new study, titled, "Brain Tumor Drugs Market, 2022-2028." As per the study, the market stood at USD 2.35 billion in 2020 and hit USD 2.83 billion in 2022. It is set to exhibit a CAGR of 10.4% in the forecast period between 2022-2028.

Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/brain-tumor-drugs-market-105025

Geographical Analysis:
• North America (The U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• The Middle East & Africa (South Africa, GCC, and the Rest of the Middle East & Africa)
NBTS Provides $100,000 to Curtana Pharmaceuticals for Researching on CT-179
In May 2020, National Brain Tumor Society (NBTS) offered $100,000 to conduct research on CT-179, a novel drug candidate developed by Curtana Pharmaceuticals for the treatment of glioblastoma. As per one of the company officials, "The additional funding will help us learn more about the capacity of this drug."

COVID-19 to Bolster Growth Owing to Increasing Sales of Oncology Drugs
Several pharmaceutical companies are striving to improve their supply chain management and quality control by investing huge sums amid the COVID-19 pandemic. Roche's quarterly reports of 2020, for instance, mentions that sales of its pharmaceutical division surged by 7%. Its supply chain of tests and medicines were intact throughout the pandemic. The growth was majorly driven by oncology drugs, such as Perjeta and Tecentriq. Our research report will help you regain your business confidence by utilizing the best available strategy.

To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/brain-tumor-drugs-market-105025

Report Coverage-
We follow a comprehensive research methodology that focuses majorly on delivering authentic and authentic information. We have utilized a data triangulation model which would aid us to offer accurate estimates and gauge the overall dynamics of the brain cancer drugs market. We also have gained access to multiple global and regional paid databases for delivering the latest information so that you can invest only in the vital areas.

Emergence of Combination Therapy Worldwide to Boost Brain Tumor Drugs Market Growth
The urgent need to provide advanced patient care for a large number of brain disorders is compelling manufacturers worldwide to conduct extensive research and development activities. They are conducting novel experiments to introduce combination therapies with pre-existing or new drug molecules. Hence, it is resulting in the increasing number of pipeline candidates for drugs of brain tumor. Mateon Therapeutics Inc., for instance, received the U.S. FDA approval for OT101/Trabedersen in September 2019. It will be used to treat diffuse intrinsic pontine glioma (DIPG).

Speak To Our Analyst:
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/brain-tumor-drugs-market-105025

Rising Prevalence of This Cancer to Accelerate the Glioblastoma Segment
Based on the distribution channel, the market is trifurcated into hospital pharmacies, retail pharmacies, and others. By the therapy type, it is classified into chemotherapy, targeted therapy, immunotherapy, and others. Here's a brief glimpse of the indication criterion:
• By Indication: The market is categorized into glioblastoma, meningioma, pituitary tumors, and others. Out of these, the glioblastoma segment procured the highest brain tumor drugs market share in 2020 and is set to dominate in the upcoming years. The rising cases of this cancer are expected to propel growth. Coupled with this, the early diagnosis rate of glioblastoma and increasing awareness programs would aid growth.

Asia Pacific to Grow Steadily Fueled by Increasing Geriatric Population
• North America: The region earned USD 1.12 billion in 2020 in terms of revenue and is estimated to dominate the market in the near future. This growth is attributable to the increasing launch of innovative products and the early access to technologically advanced treatment options.
• Europe: It held the second position in 2020 because of the rising awareness programs conducted by governments and the investments in the development of novel brain tumor drugs.
• Asia Pacific: The region would showcase the highest CAGR in the forthcoming years on account of the rising geriatric population and higher prevalence of brain cancer in Japan, China, and India.

Fast Track Approvals and R&D Activities - Crucial Strategies of Key Companies
The market is fragmented in nature. Numerous renowned companies are trying to bag fast track approvals from regulatory bodies for their in-house brain tumor drugs. A few others are conducting R&D activities to remain at the forefront. Also, the entry of new firms in the market is expected to increase the potential of the industry. Below is one of the latest industry developments:
• December 2020: The U.S. The Food and Drug Administration (FDA) announced the approval of an investigational new drug application for Berubicin. It is meant for the treatment of adults living with a rare and aggressive brain cancer named glioblastoma.

Fortune Business Insights™ presents a list of prominent brain tumor drug providers:
• Pfizer Inc. (New York, U.S)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Novartis AG (Basel, Switzerland)
• Y-mAbs Therapeutics, Inc. (U.S)
• Merck & Co. Inc. (New Jersey, U.S)
• Johnson & Johnson (New Jersey, U.S)
• AstraZeneca (Cambridge, U.K)
• Bristol-Myers Squibb (New York, U.S)
• Other Players

Quick Buy - Brain Tumor Drugs Market Research Report:
https://www.fortunebusinessinsights.com/checkout-page/105025

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
LinkedIn: https://www.linkedin.com/company/fortune-business-insights
Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd

This release was published on openPR.